Semaglutide cuts cardiovascular risk by 20% in people with heart disease, obesity: SELECT healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
Concomitant left atrial appendage occlusion, TAVR an option for some with AF: WATCH-TAVR healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The Heart Failure Society of America (HFSA) is pleased to announce Randall C. Starling, MD, MPH, Professor of Medicine, Kaufman Center for.